Polycystic kidney disease: Pathogenesis and potential therapies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 10, 2011, Pages 1337-1343

  Takiar, Vinita ^a   Caplan, Michael J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cilium; Polycystic kidney disease; Proliferation; Signaling

Indexed keywords

CYCLIC AMP; FIBROCYSTIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; POLYCYSTIN 1; RAPAMYCIN; ROSCOVITINE; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SOMATOSTATIN; TOLVAPTAN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASOPRESSIN V2 RECEPTOR;

CELL DIVISION; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CENTRIOLE; CHLAMYDOMONAS; CILIARY MOTILITY; CILIATED EPITHELIUM; CYST FLUID; HUMAN; KIDNEY CELL; KIDNEY EPITHELIUM; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; MICROTUBULE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SECRETION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CILIA; CYCLIC AMP; CYST FLUID; HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS;

EID: 80052262467     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.11.014     Document Type: Review

References (153)

1. Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3years. Kidney Int. 2009, 76:149-168.
2. Torres V.E., Harris P.C., Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007, 369:1287-1301.
3. Wilson P.D. Polycystic kidney disease. N. Engl. J. Med. 2004, 350:151-164.
4. Connor A., Lunt P.W., Dolling C., Patel Y., Meredith A.L., Gardner A., Hamilton N.K., Dudley C.R. Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation. Am. J. Transplant. 2008, 8:232-237.
5. Consugar M.B., Wong W.C., Lundquist P.A., Rossetti S., Kubly V.J., Walker D.L., Rangel L.J., Aspinwall R., Niaudet W.P., Ozen S., David A., Velinov M., Bergstralh E.J., Bae K.T., Chapman A.B., Guay-Woodford L.M., Grantham J.J., Torres V.E., Sampson J.R., Dawson B.D., Harris P.C. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008, 74:1468-1479.
6. Baboolal K., Ravine D., Daniels J., Williams N., Holmans P., Coles G.A., Williams J.D. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int. 1997, 52:607-613.
7. O'Sullivan D.A., Torres V.E., Gabow P.A., Thibodeau S.N., King B.F., Bergstralh E.J. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 1998, 32:976-983.
8. Persu A., Devuyst O., Lannoy N., Materne R., Brosnahan G., Gabow P.A., Pirson Y., Verellen-Dumoulin C. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2000, 11:2285-2296.
9. Brook-Carter P.T., Peral B., Ward C.J., Thompson P., Hughes J., Maheshwar M.M., Nellist M., Gamble V., Harris P.C., Sampson J.R. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syndrome. Nat. Genet. 1994, 8:328-332.
10. Gabow P.A., Johnson A.M., Kaehny W.D., Kimberling W.J., Lezotte D.C., Duley I.T., Jones R.H. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992, 41:1311-1319.
11. Chapman A.B., Johnson A.M., Gabow P.A., Schrier R.W. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1994, 5:1349-1354.
12. Fick-Brosnahan G.M., Tran Z.V., Johnson A.M., Strain J.D., Gabow P.A. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int. 2001, 59:1654-1662.
13. Fick-Brosnahan G.M., Belz M.M., McFann K.K., Johnson A.M., Schrier R.W. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis. 2002, 39:1127-1134.
14. Gabow P.A., Chapman A.B., Johnson A.M., Tangel D.J., Duley I.T., Kaehny W.D., Manco-Johnson M., Schrier R.W. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1990, 38:1177-1180.
15. Schrier R.W., Johnson A.M., McFann K., Chapman A.B. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int. 2003, 64:1792-1799.
16. Gabow P.A., Kimberling W.J., Strain J.D., Manco-Johnson M.L., Johnson A.M. Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children. J. Am. Soc. Nephrol. 1997, 8:105-110.
17. Grantham J.J., Chapman A.B., Torres V.E. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 2006, 1:148-157.
18. King B.F., Torres V.E., Brummer M.E., Chapman A.B., Bae K.T., Glockner J.F., Arya K., Felmlee J.P., Grantham J.J., Guay-Woodford L.M., Bennett W.M., Klahr S., Hirschman G.H., Kimmel P.L., Thompson P.A., Miller J.P. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003, 64:2214-2221.
19. Chapman A.B., Guay-Woodford L.M., Grantham J.J., Torres V.E., Bae K.T., Baumgarten D.A., Kenney P.J., King B.F., Glockner J.F., Wetzel L.H., Brummer M.E., O'Neill W.C., Robbin M.L., Bennett W.M., Klahr S., Hirschman G.H., Kimmel P.L., Thompson P.A., Miller J.P. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003, 64:1035-1045.
20. Grantham J.J., Torres V.E., Chapman A.B., Guay-Woodford L.M., Bae K.T., King B.F., Wetzel L.H., Baumgarten D.A., Kenney P.J., Harris P.C., Klahr S., Bennett W.M., Hirschman G.N., Meyers C.M., Zhang X., Zhu F., Miller J.P. Volume progression in polycystic kidney disease. N. Engl. J. Med. 2006, 354:2122-2130.
21. Bae K.T., Tao C., Zhu F., Bost J.E., Chapman A.B., Grantham J.J., Torres V.E., Guay-Woodford L.M., Meyers C.M., Bennett W.M. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin. J. Am. Soc. Nephrol. 2009, 4:719-725.
22. O'Neill W.C., Robbin M.L., Bae K.T., Grantham J.J., Chapman A.B., Guay-Woodford L.M., Torres V.E., King B.F., Wetzel L.H., Thompson P.A., Miller J.P. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am. J. Kidney Dis. 2005, 46:1058-1064.
23. Namli S., Oflaz H., Turgut F., Alisir S., Tufan F., Ucar A., Mercanoglu F., Ecder T. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren. Fail. 2007, 29:55-59.
24. Glassman D.T., Nipkow L., Bartlett S.T., Jacobs S.C. Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J. Urol. 2000, 164:661-664.
25. Perrone R.D., Ruthazer R., Terrin N.C. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001, 38:777-784.
26. Fick G.M., Johnson A.M., Hammond W.S., Gabow P.A. Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995, 5:2048-2056.
27. Peters D.J., Breuning M.H. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001, 358:1439-1444.
28. Daoust M.C., Reynolds D.M., Bichet D.G., Somlo S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 1995, 25:733-736.
29. McConnell R.S., Rubinsztein D.C., Fannin T.F., McKinstry C.S., Kelly B., Bailey I.C., Hughes A.E. Autosomal dominant polycystic kidney disease unlinked to the PKD1 and PKD2 loci presenting as familial cerebral aneurysm. J. Med. Genet. 2001, 38:238-240.
30. Norby S., Schwartz M. Possible locus for polycystic kidney disease on chromosome 2. Lancet 1990, 336:323-324.
31. Hateboer N., v Dijk M.A., Bogdanova N., Coto E., Saggar-Malik A.K., San Millan J.L., Torra R., Breuning M., Ravine D. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999, 353:103-107.
32. Harris P.C., Bae K.T., Rossetti S., Torres V.E., Grantham J.J., Chapman A.B., Guay-Woodford L.M., King B.F., Wetzel L.H., Baumgarten D.A., Kenney P.J., Consugar M., Klahr S., Bennett W.M., Meyers C.M., Zhang Q.J., Thompson P.A., Zhu F., Miller J.P. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2006, 17:3013-3019.
33. Rossetti S., Consugar M.B., Chapman A.B., Torres V.E., Guay-Woodford L.M., Grantham J.J., Bennett W.M., Meyers C.M., Walker D.L., Bae K., Zhang Q.J., Thompson P.A., Miller J.P., Harris P.C. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2007, 18:2143-2160.
34. Wilson P.D., Geng L., Li X., Burrow C.R. The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia. Lab. Invest. 1999, 79:1311-1323.
35. Chauvet V., Tian X., Husson H., Grimm D.H., Wang T., Hiesberger T., Igarashi P., Bennett A.M., Ibraghimov-Beskrovnaya O., Somlo S., Caplan M.J. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J. Clin. Invest. 2004, 114:1433-1443.
36. Low S.H., Vasanth S., Larson C.H., Mukherjee S., Sharma N., Kinter M.T., Kane M.E., Obara T., Weimbs T. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev. Cell 2006, 10:57-69.
37. Qamar S., Vadivelu M., Sandford R. TRP channels and kidney disease: lessons from polycystic kidney disease. Biochem. Soc. Trans. 2007, 35:124-128.
38. Li X., Luo Y., Starremans P.G., McNamara C.A., Pei Y., Zhou J. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat. Cell Biol. 2005, 7:1202-1212.
39. Tobin J.L., Beales P.L. The nonmotile ciliopathies. Genet. Med. 2009, 11:386-402.
40. Zaghloul N.A., Katsanis N. Mechanistic insights into Bardet-Biedl syndrome, a model ciliopathy. J. Clin. Invest. 2009, 119:428-437.
41. Qian F., Watnick T.J., Onuchic L.F., Germino G.G. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996, 87:979-987.
42. Lu W., Peissel B., Babakhanlou H., Pavlova A., Geng L., Fan X., Larson C., Brent G., Zhou J. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat. Genet. 1997, 17:179-181.
43. Lu W., Fan X., Basora N., Babakhanlou H., Law T., Rifai N., Harris P.C., Perez-Atayde A.R., Rennke H.G., Zhou J. Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat. Genet. 1999, 21:160-161.
44. Lantinga-van Leeuwen I.S., Dauwerse J.G., Baelde H.J., Leonhard W.N., van de Wal A., Ward C.J., Verbeek S., Deruiter M.C., Breuning M.H., de Heer E., Peters D.J. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum. Mol. Genet. 2004, 13:3069-3077.
45. Kurbegovic A., Cote O., Couillard M., Ward C.J., Harris P.C., Trudel M. Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes. Hum. Mol. Genet. 2010, 19:1174-1189.
46. Piontek K., Menezes L.F., Garcia-Gonzalez M.A., Huso D.L., Germino G.G. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat. Med. 2007, 13:1490-1495.
47. Lantinga-van Leeuwen I.S., Leonhard W.N., van der Wal A., Breuning M.H., de Heer E., Peters D.J. Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum. Mol. Genet. 2007, 16:3188-3196.
48. Koptides M., Mean R., Demetriou K., Pierides A., Deltas C.C. Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum. Mol. Genet. 2000, 9:447-452.
49. Takakura A., Contrino L., Zhou X., Bonventre J.V., Sun Y., Humphreys B.D., Zhou J. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum. Mol. Genet. 2009, 18:2523-2531.
50. Takaki E., Fujimoto M., Nakahari T., Yonemura S., Miyata Y., Hayashida N., Yamamoto K., Vallee R.B., Mikuriya T., Sugahara K., Yamashita H., Inouye S., Nakai A. Heat shock transcription factor 1 is required for maintenance of ciliary beating in mice. J. Biol. Chem. 2007, 282:37285-37292.
51. Braiman A., Priel Z. Efficient mucociliary transport relies on efficient regulation of ciliary beating. Respir. Physiol. Neurobiol. 2008, 163:202-207.
52. Ibanez-Tallon I., Pagenstecher A., Fliegauf M., Olbrich H., Kispert A., Ketelsen U.P., North A., Heintz N., Omran H. Dysfunction of axonemal dynein heavy chain Mdnah5 inhibits ependymal flow and reveals a novel mechanism for hydrocephalus formation. Hum. Mol. Genet. 2004, 13:2133-2141.
53. Lechtreck K.F., Delmotte P., Robinson M.L., Sanderson M.J., Witman G.B. Mutations in Hydin impair ciliary motility in mice. J. Cell Biol. 2008, 180:633-643.
54. Singla V., Reiter J.F. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science 2006, 313:629-633.
55. Zimmermann K.W. Beiträge zur Kenntnis einiger Drüsen und Epithelien. Arch. mikr. Anat. 1898, 52:552-706.
56. Davis E.E., Brueckner M., Katsanis N. The emerging complexity of the vertebrate cilium: new functional roles for an ancient organelle. Dev. Cell 2006, 11:9-19.
57. Seeley E.S., Nachury M.V. The perennial organelle: assembly and disassembly of the primary cilium. J. Cell Sci. 2010, 123:511-518.
58. Cardenas-Rodriguez M., Badano J.L. Ciliary biology: understanding the cellular and genetic basis of human ciliopathies. Am. J. Med. Genet. C Semin. Med. Genet. 2009, 151C:263-280.
59. Baker K., Beales P.L. Making sense of cilia in disease: the human ciliopathies. Am. J. Med. Genet. C Semin. Med. Genet. 2009, 151C:281-295.
60. Quarmby L.M., Parker J.D. Cilia and the cell cycle?. J. Cell Biol. 2005, 169:707-710.
61. Pan J., Snell W. The primary cilium: keeper of the key to cell division. Cell 2007, 129:1255-1257.
62. Dingemans K.P. The relation between cilia and mitoses in the mouse adenohypophysis. J. Cell Biol. 1969, 43:361-367.
63. Fonte V.G., Searls R.L., Hilfer S.R. The relationship of cilia with cell division and differentiation. J. Cell Biol. 1971, 49:226-229.
64. Sorokin S. Centrioles and the formation of rudimentary cilia by fibroblasts and smooth muscle cells. J. Cell Biol. 1962, 15:363-377.
65. Yoder B.K. Role of primary cilia in the pathogenesis of polycystic kidney disease. J. Am. Soc. Nephrol. 2007, 18:1381-1388.
66. Rohatgi R., Snell W.J. The ciliary membrane. Curr. Opin. Cell Biol. 2010, 22:541-546.
67. Pedersen L.B., Rosenbaum J.L. Intraflagellar transport (IFT) role in ciliary assembly, resorption and signalling. Curr. Top. Dev. Biol. 2008, 85:23-61.
68. Pearson C.G., Culver B.P., Winey M. Centrioles want to move out and make cilia. Dev. Cell 2007, 13:319-321.
69. Piel M., Meyer P., Khodjakov A., Rieder C.L., Bornens M. The respective contributions of the mother and daughter centrioles to centrosome activity and behavior in vertebrate cells. J. Cell Biol. 2000, 149:317-330.
70. Anderson R.G. The three-dimensional structure of the basal body from the rhesus monkey oviduct. J. Cell Biol. 1972, 54:246-265.
71. Deane J.A., Cole D.G., Seeley E.S., Diener D.R., Rosenbaum J.L. Localization of intraflagellar transport protein IFT52 identifies basal body transitional fibers as the docking site for IFT particles. Curr. Biol. 2001, 11:1586-1590.
72. Tachi S., Tachi C., Lindner H.R. Influence of ovarian hormones on formation of solitary cilia and behavior of the centrioles in uterine epithelial cells of the rat. Biol. Reprod. 1974, 10:391-403.
73. Rosenbaum J.L., Witman G.B. Intraflagellar transport. Nat. Rev. Mol. Cell Biol. 2002, 3:813-825.
74. Kozminski K.G., Johnson K.A., Forscher P., Rosenbaum J.L. A motility in the eukaryotic flagellum unrelated to flagellar beating. Proc. Natl. Acad. Sci. USA 1993, 90:5519-5523.
75. Piperno G., Mead K. Transport of a novel complex in the cytoplasmic matrix of Chlamydomonas flagella. Proc. Natl. Acad. Sci. USA 1997, 94:4457-4462.
76. Johnson K.A., Rosenbaum J.L. Polarity of flagellar assembly in Chlamydomonas. J. Cell Biol. 1992, 119:1605-1611.
77. Lin F., Hiesberger T., Cordes K., Sinclair A.M., Goldstein L.S., Somlo S., Igarashi P. Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc. Natl. Acad. Sci. USA 2003, 100:5286-5291.
78. Scholey J.M. Intraflagellar transport. Annu. Rev. Cell Dev. Biol. 2003, 19:423-443.
79. Praetorius H.A., Spring K.R. Bending the MDCK cell primary cilium increases intracellular calcium. J. Membr. Biol. 2001, 184:71-79.
80. Yoder B.K., Richards W.G., Sweeney W.E., Wilkinson J.E., Avener E.D., Woychik R.P. Insertional mutagenesis and molecular analysis of a new gene associated with polycystic kidney disease. Proc. Assoc. Am. Physicians 1995, 107:314-323.
81. Pazour G.J., Dickert B.L., Vucica Y., Seeley E.S., Rosenbaum J.L., Witman G.B., Cole D.G. Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene tg737, are required for assembly of cilia and flagella. J. Cell Biol. 2000, 151:709-718.
82. Lehman J.M., Michaud E.J., Schoeb T.R., Aydin-Son Y., Miller M., Yoder B.K. The Oak Ridge Polycystic Kidney mouse: modeling ciliopathies of mice and men. Dev. Dyn. 2008, 237:1960-1971.
83. Barr M.M., Sternberg P.W. A polycystic kidney-disease gene homologue required for male mating behaviour in C. elegans. Nature 1999, 401:386-389.
84. Pazour G.J., San Agustin J.T., Follit J.A., Rosenbaum J.L., Witman G.B. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr. Biol. 2002, 12:R378-R380.
85. Yoder B.K., Hou X., Guay-Woodford L.M. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J. Am. Soc. Nephrol. 2002, 13:2508-2516.
86. Ward C.J., Yuan D., Masyuk T.V., Wang X., Punyashthiti R., Whelan S., Bacallao R., Torra R., LaRusso N.F., Torres V.E., Harris P.C. Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum. Mol. Genet. 2003, 12:2703-2710.
87. Hildebrandt F., Zhou W. Nephronophthisis-associated ciliopathies. J. Am. Soc. Nephrol. 2007, 18:1855-1871.
88. Otto E.A., Schermer B., Obara T., O'Toole J.F., Hiller K.S., Mueller A.M., Ruf R.G., Hoefele J., Beekmann F., Landau D., Foreman J.W., Goodship J.A., Strachan T., Kispert A., Wolf M.T., Gagnadoux M.F., Nivet H., Antignac C., Walz G., Drummond I.A., Benzing T., Hildebrandt F. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat. Genet. 2003, 34:413-420.
89. Schwartz E.A., Leonard M.L., Bizios R., Bowser S.S. Analysis and modeling of the primary cilium bending response to fluid shear. Am. J. Physiol. 1997, 272:F132-F138.
90. Praetorius H.A., Spring K.R. Removal of the MDCK cell primary cilium abolishes flow sensing. J. Membr. Biol. 2003, 191:69-76.
91. Nauli S.M., Alenghat F.J., Luo Y., Williams E., Vassilev P., Li X., Elia A.E., Lu W., Brown E.M., Quinn S.J., Ingber D.E., Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 2003, 33:129-137.
92. Wang S., Zhang J., Nauli S.M., Li X., Starremans P.G., Luo Y., Roberts K.A., Zhou J. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol. Cell. Biol. 2007, 27:3241-3252.
93. Nauli S.M., Kawanabe Y., Kaminski J.J., Pearce W.J., Ingber D.E., Zhou J. Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1. Circulation 2008, 117:1161-1171.
94. Xu C., Rossetti S., Jiang L., Harris P.C., Brown-Glaberman U., Wandinger-Ness A., Bacallao R., Alper S.L. Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling. Am. J. Physiol. Ren. Physiol. 2007, 292:F930-F945.
95. Bhunia A.K., Piontek K., Boletta A., Liu L., Qian F., Xu P.N., Germino F.J., Germino G.G. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002, 109:157-168.
96. Nishio S., Hatano M., Nagata M., Horie S., Koike T., Tokuhisa T., Mochizuki T. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J. Clin. Invest. 2005, 115:910-918.
97. Shillingford J.M., Murcia N.S., Larson C.H., Low S.H., Hedgepeth R., Brown N., Flask C.A., Novick A.C., Goldfarb D.A., Kramer-Zucker A., Walz G., Piontek K.B., Germino G.G., Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 2006, 103:5466-5471.
98. Puri S., Magenheimer B.S., Maser R.L., Ryan E.M., Zien C.A., Walker D.D., Wallace D.P., Hempson S.J., Calvet J.P. Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J. Biol. Chem. 2004, 279:55455-55464.
99. Kim E., Arnould T., Sellin L.K., Benzing T., Fan M.J., Gruning W., Sokol S.Y., Drummond I., Walz G. The polycystic kidney disease 1 gene product modulates Wnt signaling. J. Biol. Chem. 1999, 274:4947-4953.
100. Eggenschwiler J.T., Anderson K.V. Cilia and developmental signaling. Annu. Rev. Cell Dev. Biol. 2007, 23:345-373.
101. Christensen S.T., Ott C.M. Cell signaling. A ciliary signaling switch. Science 2007, 317:330-331.
102. Qian C.N., Knol J., Igarashi P., Lin F., Zylstra U., Teh B.T., Williams B.O. Cystic renal neoplasia following conditional inactivation of apc in mouse renal tubular epithelium. J. Biol. Chem. 2005, 280:3938-3945.
103. Saburi S., Hester I., Fischer E., Pontoglio M., Eremina V., Gessler M., Quaggin S.E., Harrison R., Mount R., McNeill H. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease. Nat. Genet. 2008, 40:1010-1015.
104. Corbit K.C., Shyer A.E., Dowdle W.E., Gaulden J., Singla V., Chen M.H., Chuang P.T., Reiter J.F. Kif3a constrains beta-catenin-dependent Wnt signalling through dual ciliary and non-ciliary mechanisms. Nat. Cell Biol. 2008, 10:70-76.
105. Veland I.R., Awan A., Pedersen L.B., Yoder B.K., Christensen S.T. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol. 2009, 111:39-53.
106. Grantham J.J. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances. Am. J. Kidney Dis. 1996, 28:788-803.
107. Ong A.C., Harris P.C. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int. 2005, 67:1234-1247.
108. Boca M., Distefano G., Qian F., Bhunia A.K., Germino G.G., Boletta A. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J. Am. Soc. Nephrol. 2006, 17:637-647.
109. Deane J.A., Ricardo S.D. Polycystic kidney disease and the renal cilium. Nephrology (Carlton) 2007, 12:559-564.
110. Gallagher A.R., Hoffmann S., Brown N., Cedzich A., Meruvu S., Podlich D., Feng Y., Konecke V., de Vries U., Hammes H.P., Gretz N., Witzgall R. A truncated polycystin-2 protein causes polycystic kidney disease and retinal degeneration in transgenic rats. J. Am. Soc. Nephrol. 2006, 17:2719-2730.
111. Belibi F.A., Reif G., Wallace D.P., Yamaguchi T., Olsen L., Li H., Helmkamp G.M., Grantham J.J. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004, 66:964-973.
112. Torres V.E. Type II calcimimetics and polycystic kidney disease: unanswered questions. J. Am. Soc. Nephrol. 2009, 20:1421-1425.
113. Herrera G.A. C-erb B-2 amplification in cystic renal disease. Kidney Int. 1991, 40:509-513.
114. Grimm D.H., Karihaloo A., Cai Y., Somlo S., Cantley L.G., Caplan M.J. Polycystin-2 regulates proliferation and branching morphogenesis in kidney epithelial cells. J. Biol. Chem. 2006, 281:137-144.
115. Mostov K.E. mTOR is out of control in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 2006, 103:5247-5248.
116. Ibraghimov-Beskrovnaya O. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 2007, 6:776-779.
117. Davidow C.J., Maser R.L., Rome L.A., Calvet J.P., Grantham J.J. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int. 1996, 50:208-218.
118. Grantham J.J., Ye M., Davidow C., Holub B., Sharma M. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995, 6:1242-1249.
119. Sullivan L.P., Wallace D.P., Gover T., Welling P.A., Yamaguchi T., Maser R., Eppler J.W., Grantham J.J. Sulfonylurea-sensitive K(+) transport is involved in Cl(-) secretion and cyst trowth by cultured ADPKD cells. J. Am. Soc. Nephrol. 2002, 13:2619-2627.
120. Albaqumi M., Srivastava S., Li Z., Zhdnova O., Wulff H., Itani O., Wallace D.P., Skolnik E.Y. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 2008, 74:740-749.
121. Xu N., Glockner J.F., Rossetti S., Babovich-Vuksanovic D., Harris P.C., Torres V.E. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J. Nephrol. 2006, 19:529-534.
122. Magenheimer B.S., St John P.L., Isom K.S., Abrahamson D.R., De Lisle R.C., Wallace D.P., Maser R.L., Grantham J.J., Calvet J.P. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+), K(+), 2Cl(-) Co-transporter-dependent cystic dilation. J. Am. Soc. Nephrol. 2006, 17:3424-3437.
123. Li H., Findlay I.A., Sheppard D.N. The relationship between cell proliferation, Cl-secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 2004, 66:1926-1938.
124. Anderson M.P., Berger H.A., Rich D.P., Gregory R.J., Smith A.E., Welsh M.J. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991, 67:775-784.
125. Putnam W.C., Swenson S.M., Reif G.A., Wallace D.P., Helmkamp G.M., Grantham J.J. Identification of a forskolin-like molecule in human renal cysts. J. Am. Soc. Nephrol. 2007, 18:934-943.
126. Ye M., Grant M., Sharma M., Elzinga L., Swan S., Torres V.E., Grantham J.J. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J. Am. Soc. Nephrol. 1992, 3:984-994.
127. Gattone V.H., Wang X., Harris P.C., Torres V.E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 2003, 9:1323-1326.
128. Torres V.E., Wang X., Qian Q., Somlo S., Harris P.C., Gattone V.H. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 2004, 10:363-364.
129. Yamaguchi T., Nagao S., Kasahara M., Takahashi H., Grantham J.J. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am. J. Kidney Dis. 1997, 30:703-709.
130. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 2000, 351(Pt 2):289-305.
131. Danielsen H., Pedersen E.B., Nielsen A.H., Herlevsen P., Kornerup H.J., Posborg V. Expansion of extracellular volume in early polycystic kidney disease. Acta Med. Scand. 1986, 219:399-405.
132. Gattone V.H., Maser R.L., Tian C., Rosenberg J.M., Branden M.G. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev. Genet. 1999, 24:309-318.
133. Hogan M.C., Masyuk T.V., Page L.J., Kubly V.J., Bergstralh E.J., Li X., Kim B., King B.F., Glockner J., Holmes D.R., Rossetti S., Harris P.C., LaRusso N.F., Torres V.E. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J. Am. Soc. Nephrol. 2010, 21:1052-1061.
134. Miyazaki T., Fujiki H., Yamamura Y., Nakamura S., Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc. Drug Rev. 2007, 25:1-13.
135. Patel V., Chowdhury R., Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr. Opin. Nephrol. Hypertens. 2009, 18:99-106.
136. Yang B., Sonawane N.D., Zhao D., Somlo S., Verkman A.S. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 2008, 19:1300-1310.
137. Cowley B.D. Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications. Drugs 2004, 64:1285-1294.
138. Gattone V.H. Emerging therapies for polycystic kidney disease. Curr. Opin. Pharmacol. 2005, 5:535-542.
139. Bukanov N.O., Smith L.A., Klinger K.W., Ledbetter S.R., Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006, 444:949-952.
140. Park E.Y., Sung Y.H., Yang M.H., Noh J.Y., Park S.Y., Lee T.Y., Yook Y.J., Yoo K.H., Roh K.J., Kim I., Hwang Y.H., Oh G.T., Seong J.K., Ahn C., Lee H.W., Park J.H. Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice. J. Biol. Chem. 2009, 284:7214-7222.
141. Omori S., Hida M., Fujita H., Takahashi H., Tanimura S., Kohno M., Awazu M. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J. Am. Soc. Nephrol. 2006, 17:1604-1614.
142. Wahl P.R., Serra A.L., Le Hir M., Molle K.D., Hall M.N., Wuthrich R.P. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant. 2006, 21:598-604.
143. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., Abraham R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 1995, 270:815-822.
144. Cardenas M.E., Cutler N.S., Lorenz M.C., Di Como C.J., Heitman J. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 1999, 13:3271-3279.
145. Shillingford J.M., Piontek K.B., Germino G.G., Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 2009, 21:489-497.
146. Torres V.E., Boletta A., Chapman A., Gattone V., Pei Y., Qian Q., Wallace D.P., Weimbs T., Wuthrich R.P. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin. J. Am. Soc. Nephrol. 2010, 5:1312-1329.
147. Serra A.L., Poster D., Kistler A.D., Krauer F., Raina S., Young J., Rentsch K.M., Spanaus K.S., Senn O., Kristanto P., Scheffel H., Weishaupt D., Wuthrich R.P. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010, 363:820-829.
148. Walz G., Budde K., Mannaa M., Nurnberger J., Wanner C., Sommerer C., Kunzendorf U., Banas B., Horl W.H., Obermuller N., Arns W., Pavenstadt H., Gaedeke J., Buchert M., May C., Gschaidmeier H., Kramer S., Eckardt K.U. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010, 363:830-840.
149. Li X., Magenheimer B.S., Xia S., Johnson T., Wallace D.P., Calvet J.P., Li R. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat. Med. 2008, 14:863-868.
150. Benson C., White J., De Bono J., O'Donnell A., Raynaud F., Cruickshank C., McGrath H., Walton M., Workman P., Kaye S., Cassidy J., Gianella-Borradori A., Judson I., Twelves C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7days every 21days. Br. J. Cancer 2007, 96:29-37.
151. Natoli T.A., Smith L.A., Rogers K.A., Wang B., Komarnitsky S., Budman Y., Belenky A., Bukanov N.O., Dackowski W.R., Husson H., Russo R.J., Shayman J.A., Ledbetter S.R., Leonard J.P., Ibraghimov-Beskrovnaya O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med. 2010, 16:788-792.
152. Cao Y., Semanchik N., Lee S.H., Somlo S., Barbano P.E., Coifman R., Sun Z. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc. Natl. Acad. Sci. USA 2009, 106:21819-21824.
153. Xia S., Li X., Johnson T., Seidel C., Wallace D.P., Li R. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 2010, 137:1075-1084.